Shanghai Pharmaceuticals Holding Co.,Ltd. (601607.SH) announced that its subsidiary Shandong Xinyi Pharmaceutical Co., Ltd. (Shandong Xinyi) has received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration for its nicorandil tablets. The drug has successfully passed the consistency evaluation for generic drug quality and efficacy. Nicorandil tablets are used for the treatment of angina pectoris.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.